Randomized phase 2 study of the addition of ramucirumab or merestinib to standard first line therapy for advanced or metastatic biliary tract cancer

Juan Valle, et al.

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Randomized phase 2 study of the addition of ramucirumab or merestinib to standard first line therapy for advanced or metastatic biliary tract cancer'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science